key: cord-0789449-mba886ox
authors: Li, Yi; Wang, Xiaozeng; Bao, Dan; Liao, Zhuan; Li, Jing; Han, Xiao; Wang, Heyang; Xu, Kai; Li, Zhaoshen; Stone, Gregg W.; Han, Yaling
title: Optimal AntiPlatelet therapy for prevention of gastrointestinal injury evaluated by Ankon magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial
date: 2020-06-15
journal: Am Heart J
DOI: 10.1016/j.ahj.2020.06.004
sha: 75a766a067e2a2cd1ad2cb18d956e808bbb49d90
doc_id: 789449
cord_uid: mba886ox

Abstract Background Gastrointestinal injury is a common complication in patients treated with antiplatelet agents after percutaneous coronary intervention (PCI). However, the effects of different antiplatelet regimens on the incidence and severity of gastrointestinal injury have not been well studied, principally due to the lack of a low-risk sensitive and accurate detection system. Trial design. OPT-PEACE is a multicenter, randomized, double-blind, placebo-controlled trial. Gastrointestinal injury will be evaluated with the ANKON magnetically controlled capsule endoscopy system (AMCE), a minimally invasive approach for detecting mucosal lesions in the stomach, duodenum and small intestine. Patients without AMCE-detected gastrointestinal erosions, ulceration or bleeding after drug-eluting stent implantation are enrolled and treated with open-label aspirin (100mg/day) plus clopidogrel (75mg/day) for 6months. Thereafter, 480 event-free patients will undergo repeat AMCE and are randomly assigned in a 1:1:1 ratio to receive aspirin plus clopidogrel, aspirin plus placebo or clopidogrel plus placebo for an additional 6months. A final AMCE is performed at 12months. The primary endpoint is the incidence of gastric or intestinal mucosal lesions (erosions, ulceration or bleeding) within 12months after enrollment. Conclusions OPT-PEACE is the first study to investigate the incidence and severity of gastrointestinal injury in patients receiving different antiplatelet therapy regimens after stent implantation. This trial will inform clinical decision-making for personalized antiplatelet therapy post-PCI.

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the cornerstone for prevention of atherothrombosis after percutaneous coronary intervention (PCI) in patients with coronary artery disease We are therefore performing a double-blind, placebo-controlled randomized trial examining the incidence of gastrointestinal injury evaluated by AMCE in patients treated with a 12-month DAPT regimen vs. a 6-month DAPT regimen followed by 6 months of aspirin monotherapy or clopidogrel monotherapy after DES implantation.

Study objectives and hypothesis. The principal hypothesis of the trial is that following 6 months of DAPT, antiplatelet monotherapy with aspirin or clopidogrel between 6 and 12 months after DES implantation is superior to 12 months of DAPT for preventing gastrointestinal injury detected by AMCE. Thus, the primary study objective is to determine J o u r n a l P r e -p r o o f 6 In addition, an exploratory objective is to establish a gastrointestinal mucosal injury scoring system that may identify patients at future risk for clinical gastrointestinal bleeding during long-term APT. For this purpose, two previously developed scoring systems will be used to assess the degree of mucosal injury observed by AMCE: 1) The modified Lanza score (MLS) [16] , and 2) a separate 5-point scoring system [17] (Table 1) .

OPT-PEACE is a multicenter, randomized, double-blind, placebo-controlled trial. The trial organization and key committees appear in the appendix. The investigator team at each center consists of cardiologists and gastroenterologists or endoscopists. Executive and steering committees are responsible for the medical, scientific, and operational conduct of the study. The executive committee is responsible for the integrity of data analysis and reporting of results. An independent clinical events committee will adjudicate all cardiovascular and gastrointestinal events. Endoscopic images will be analyzed by an independent core laboratory.

An independent data safety monitoring board (DSMB) will review unblinded interim data at regular intervals. The data to be reviewed will consist of gastrointestinal mucosa lesions, all bleeding, major adverse cardiovascular events, stent thrombosis as well as other serious adverse events, in order to identify potential safety issues. Based on the safety data, the DSMB may advise the Steering Committee if, in their view, the randomized data provide evidence that may warrant early termination for either efficacy or safety. All final decisions regarding trial modifications rest with the Executive Committee. Study population and AMCE procedure. Patients with either stable coronary artery disease or low-risk acute coronary syndromes without ST-segment elevation (GRACE score <140) after complete coronary revascularization with at least 1 but not more than 4 contemporary DES will be considered for enrollment. Clinical inclusion and exclusion criteria are listed in Table 2 . Patients meeting all entry criteria will provide informed written consent and then undergo a screening AMCE examination 30-120 hours after successful PCI.

The AMCE system is comprised of a magnetic navigation control system, a portable data recorder and a capsule position detector ( Figure 1 ). The capsule endoscope (known as an endoscopic robot) has a length of 27 mm and a diameter of 11 mm and contains a permanent magnet (Figure 1-a) . It provides a 140° viewing angle, a 30 mm depth of field and operates for at least 10 hours after ingestion. The activated capsule is swallowed into the digestive tract and continually records the condition of digestive tract mucosa at 2 frames/sec. After reaching the gastric cavity, the endoscopic capsule is navigated by the external magnetic control system to Subjects do not eat or drink any colored liquid or syrup after 8:00 pm the day before AMCE examination. On the following morning the subject is administered 10 ml of simethicone (Menarini Group, Florence, Italy) as a defoaming agent to clean the stomach cavity 40 minutes before the examination, and drinks water (~500-1000 ml) until feeling stomach fullness. During examination, if the gastric cavity is not filled with sufficient liquid to enable navigation of the capsule, the subject will drink additional water.

After the whole stomach is examined, subjects continue to wear the portable recorder for visualization of the duodenum and small intestine. The capsule is ultimately excreted. Standard magnetic resonance imaging procedures are prohibited before capsule excretion. If the capsule is not found to be excreted within two weeks after examination, the subject returns to the hospital for detection of the capsule by a position detector or abdominal X-ray to confirm whether the capsule is still in the body. If it is, endoscopy may be performed to remove the capsule.

Those undergoing successful screening AMCE exam (visualization of the entire upper gastrointestinal tract and small intestine) and with no sites of erosion, ulceration or bleeding J o u r n a l P r e -p r o o f 9 will be enrolled in the trial. Consented patients in whom the baseline screening AMCE was not performed, was not evaluable or was positive (i.e. erosion, ulceration or bleeding present) will be followed for 30 days only for safety surveillance.

Study treatments, randomization and follow-up. All enrolled patients with a negative screening AMCE examination will be treated with open-label aspirin (100 mg/day) plus clopidogrel (75 mg/day) for 6 months. Proton pump inhibitors or other gastric mucosal protectant agents may not be used after study enrollment unless a clear clinical indication has developed (e.g. new gastrointestinal bleeding or documented ulcer). Eligibility for randomization (including medication adherence and the interval occurrence of adverse events) will be evaluated in this group at 6 months (±2 weeks). At this time patients free from interval major adverse ischemic or clinically overt bleeding events and otherwise without any exclusion criteria (Table 3) will undergo a second AMCE examination before randomization. Patients successfully completing this exam are then randomly assigned in a 1:1:1 ratio to receive aspirin plus clopidogrel, aspirin plus clopidogrel-placebo or clopidogrel plus aspirin-placebo for an additional 6 months in a double blinded manner. The placebos of aspirin and clopidogrel, having an identical appearance to the original agents, were produced by a GMP certificated manufacturing company. All drugs (including placebos) were packaged and coded by a contract research organization. A final in-person visit will be performed at 6 months (±2 weeks) after randomization during to assess study medication adherence and adverse events, after which a third AMCE examination will be performed ( Figure 3) .

A Helicobacter Pylori (HP) breath test will be performed after the screening AMCE exam to document HP infection status. HP eradication therapy is not mandatory but is allowed per performed at baseline and every 2 months after enrollment, until withdrawal or termination of the study. Platelet function testing, including adenosine diphosphate-induced platelet aggregation by light transmission aggregometry and VerifyNow aspirin and P2Y12 testing assessment, will be performed at baseline screening, randomization and at the end of the study in first 102 enrolled patients (34 per group) as a platelet function substudy.

Blinding and unblinding. The study utilizes a double-blind design with matching placebo for aspirin and clopidogrel. The patients, study site research personnel, and treating physicians will not be aware of treatments received. In emergency situations the blind may be broken if absolutely necessary for the treating physician to provide optimal management. Study endpoints and definitions. The primary and secondary endpoints are shown in Table 4 . The primary endpoint is the incidence of gastric or intestinal mucosal injury occurring within 12 months after enrollment, defined as erosion, ulceration or bleeding The primary endpoint will be assessed in the 12-month DAPT group compared to the pooled 6-month DAPT plus 6-month aspirin and clopidogrel monotherapy groups. Secondary endpoints will also be assessed in these groups. The primary endpoint and all secondary endpoints will also be compared across the 3 groups, and for all single group vs. group comparisons (12-month DAPT vs 6-month DAPT plus 6-month aspirin monotherapy; 12-month DAPT vs 6-month DAPT plus 6-month clopidogrel monotherapy; and 6-month DAPT plus 6-month aspirin monotherapy vs. 6-month DAPT plus 6-month clopidogrel monotherapy).

The primary and secondary endpoints will be also analyzed in the following clinically relevant pre-specified subgroups: age (65 year cut-off), sex, diabetes mellitus, chronic kidney disease (eGFR 60 mL/min/1.73m 2 cut-off), acute coronary syndrome, prior history of gastrointestinal bleeding (24 month cut-off), HP infection status, and DAPT duration prior to randomization (>6 months vs. 6 months). Stratum-specific odds ratios or hazard ratios with 95% confidence intervals will be calculated for each subgroup using either logistic or Cox proportional hazards models as appropriate. Formal interaction testing will be performed using the subgroup × treatment allocation as an additional term in the multivariable models.

Sample size determination and adjustment. The cumulative incidence of the primary endpoint of gastric or intestinal mucosal lesions within 12 months is estimated to be Journal Pre-proof J o u r n a l P r e -p r o o f 12 47% in patients who received 12 months of DAPT and 30% in those treated with either aspirin or clopidogrel monotherapy beginning at 6 months after enrollment [22, 23] . With a 2:1 ratio in patients treated with either aspirin or clopidogrel monotherapy after 6-month DAPT vs. DAPT for 12 months, 384 evaluable patients (256 and 128 respectively) provide 90% power to detect a 17% absolute risk reduction (36% relative risk reduction) with a 2-sided type I error of 0.05.

Assuming 20% loss of evaluable primary endpoint outcome assessments due to patient withdrawal, loss to follow-up between 6 and 12 months or suboptimal AMCE visualization of the GI tract at 12 months, 480 patients are planned to be randomized. Assuming that an additional 10% of enrolled patients will not be randomized at 6 months because of adverse clinical events, non-compliance with antiplatelet therapy or lost to follow-up or withdrawal, 534 patients were initially planned to be enrolled after baseline screening. Finally, assuming that 10% of patients who undergo a screening AMCE examination will be excluded due to gastrointestinal ulcer or bleeding, approximately 593 patients were initially planned to be consented and undergo the screening AMCE examination.

Among the first 200 patients enrolled, ~25% had gastrointestinal injury at baseline by screening AMCE (despite clinically absent bleeding or gastrointestinal complaints). Of those who passed the initial exam, only ~65% were eligible for randomization; 17% of patients were noncompliant with the 6-month repeat AMCE exam, and new gastrointestinal ulceration or bleeding was found on the 6-month AMCE examination in 18% of patients. The study sample size was adjusted accordingly so 1000 patients will be screened by AMCE at baseline, with 750 patients enrolled and followed to the 6-month randomization eligibility period to achieve the 480 patient randomized goal (Figure 3 ). Subgroup analysis will be performed in patients in whom follow-up was complete vs. incomplete or otherwise affected by the COVID-19 pandemic. The primary endpoint is expected to be reported in the fourth quarter of 2020.

The OPT-PEACE trial is the first randomized study to investigate gastrointestinal endoscopic outcomes in patients receiving different APT regimens after PCI. The trial will provide new insights regarding the frequency, severity and clinical implications of subclinical and clinical gastrointestinal injury after PCI. This randomized, double-blind, placebo-controlled study will also investigate the pros and cons of different antiplatelet regimens beyond 6 months (continued DAPT vs. clopidogrel monotherapy vs. aspirin monotherapy between 6 and 12 months) after PCI, which will be informative for clinical decision-making on personalized APT. In addition, the OPT-PEACE study will provide useful insights as to the safety of AMCE as a noninvasive method for detecting gastrointestinal mucosal injury in patients receiving APT. Exclusion criteria (all must be absent)：

2) Left main disease (diameter stenosis >30%);

3) Any prior coronary stent implantation during the last year prior to the index procedure; 2) Lost to follow-up at 6 months;

3) Any event in the prior 6 months which in the opinion of the investigator results in the patient not being suitable for randomization of antiplatelet agent regimen either because of a) necessity to continue dual antiplatelet therapy (e.g. major adverse cardiovascular or cerebrovascular event within the prior 6 months or need for repeat stenting), or b) inability to continue dual antiplatelet therapy (e.g. bleeding, neoplasm, need for urgent surgery, etc.

within the prior 6 months); 4) Not presently taking both aspirin and clopidogrel, or any prior temporary discontinuation of aspirin or clopidogrel for ≥5 days; 5) Use of proton pump inhibitors or gastric mucosal protectants for more than 12 days, or for more than 4 continuous days in the 6 months prior to randomization*; 6) Unwillingness or inability to undergo the 6-month AMCE examination or the remainder of the study procedures, including the 12-month AMCE exam. *Proton pump inhibitors or any other kind of gastric mucosal protectant agents may not be used after study enrollment unless a clear clinical indication has developed (e.g. new gastrointestinal bleeding or ulcer disease). After randomization, gastric mucosa protectants may not be taken for more than 4 days continuously or in total for >10 days without a clear clinical indication.

Primary endpoint* The incidence of gastric or intestinal mucosal injuries within 12 months after enrollment, defined as erosion, ulceration or bleeding detected by planned AMCE or clinically-driven endoscopy.

1) The incidence and severity of gastric and intestinal mucosal lesions during the first 6 months after study enrollment (prior to randomization);

2) The incidence and severity of gastric and intestinal mucosal lesions after randomization (i.e. between 6 months and 12 months after study enrollment);

3) The incidence of clinically evident gastrointestinal hemorrhage attributed to the upper GI tract (or of unknown origin) during 6 months after study enrollment (prior to randomization);

4) The incidence of clinically evident gastrointestinal hemorrhage attributed to the upper GI tract (or of unknown origin) after randomization (i.e. between 6 months and 12 months after study enrollment);

5) The incidence of clinically evident gastrointestinal hemorrhage attributed to the upper GI tract (or of unknown origin) during 12 months after study enrollment; 6) Gastrointestinal symptoms (pain, nausea/vomiting, dysphagia, other) during the 12 months after enrollment; 7) All bleeding (BARC types 1-5) during the 12 months after enrollment;

8) The incidence of target lesion failure (TLF; cardiac death, target-vessel MI, or clinically-driven target lesion revascularization), during the 12 months after enrollment;

9) The incidence of net adverse clinical events (NACE, defined as TLF or BARC type 2-5 bleeding) during the 12 months after enrollment;

ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents

Upper Gastrointestinal Toxicity Associated With Long-Term Aspirin Therapy: Consequences and Prevention

Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study

Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent

Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis

Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy

Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage

Screening for Gastric and Small Intestinal Mucosal Injury with Magnetically Controlled Capsule Endoscopy in Asymptomatic Patients Taking Enteric-Coated Aspirin

Magnetic-Guided Capsule Endoscopy in the Diagnosis of Gastrointestinal Diseases in Minors

A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa

Rifaximin Reduces Number and Severity of Intestinal Lesions Associated With use of Non-steroidal Anti-inflammatory Drugs in Humans

Peptic ulcer disease

Diagnosis of gastrointestinal bleeding: A practical guide for clinicians

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium

40 on admission by echocardiography

Active hepatitis or ALT >3 times upper limits of normal at admission

Uncontrolled severe hypertension (>180/110 mmHg)

Planned use of a proton pump inhibitor, gastric mucosa protectant or any other antacid agent after study enrollment；

Required use of oral anticoagulation (warfarin or other factor II or factor X inhibitors)

Inability to take 12-month DAPT for any reason

Mandatory use of >6-month DAPT

Any comorbidity with estimated survival time <12 months (e.g. progressive cancer, chronic obstructive lung disease

Any contraindication to MRI examination, including implantation of an MRI-incompatible pacemaker, defibrillator, or other ferromagnetic material

Any condition that may interfere with any study procedures, such as dementia, immobility, alcohol use